Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data . J of Skin [Internet]. 2024 Jul. 23 [cited 2026 Mar. 17];8(4):s405. Available from: https://skin.dermsquared.com/skin/article/view/2855